Brittle bone kids get safety Follow-Up after experimental drug

NCT ID NCT07366086

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jan 28, 2026 · Last updated May 15, 2026 · Updated 16 times

Summary

This study follows children and teenagers with osteogenesis imperfecta (brittle bone disease) who previously received the drug romosozumab in an earlier trial. The goal is to monitor their long-term safety by tracking any side effects. No new treatment is given—just observation. About 71 participants will be involved.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Indiana University
RECRUITING

Indianapolis, Indiana, 46202, United States
Okayama Saiseikai Outpatient Center Hospital
RECRUITING

Okayama, Okayama-ken, 700-0013, Japan
Universitaetsklinikum Koeln
RECRUITING

Cologne, 50937, Germany
Universitaetsklinikum Wuerzburg
RECRUITING

Würzburg, 97074, Germany

Conditions

Explore the condition pages connected to this study.

OSTEOGENESIS IMPERFECTA